
A recent study, TROPHY-U-01 cohort 3, showcased promising results for treating metastatic urothelial cancer (mUC). Researchers found that combining sacituzumab govitecan (SG) with pembrolizumab resulted in a 41% objective response rate (ORR) among patients, with a 20% complete response rate. The cohort, consisting of 41 patients, saw a median progression-free survival (PFS) of 5.3 months and a median overall survival of 12.7 months. Although adverse events were noted in 61% of patients, they were mostly manageable, with neutropenia, leukopenia, and diarrhea being the most common. These findings suggest a potential new avenue for treating mUC, warranting further investigation of SG combined with checkpoint inhibitors.
Like
Save
Share